Text Size

A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment (KOSMOS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00772733
First received: October 14, 2008
Last updated: February 21, 2011
Last verified: February 2011
History of Changes
  Purpose

The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD recommendations. If relevant the general practitioner (GP) will refer patients to COPD rehabilitation conducted by relevant municipality rehabilitation teams. Secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, GPs and the municipality rehabilitation team


Condition
COPD
Chronic Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Control visits at General practitioners [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Lung function measured by spirometry [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Dyspnoea on MRC scale [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Smoking status [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
  • Rehabilitation completed in the municipality rehabilitation team [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]

Enrollment: 936
Study Start Date: October 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Diagnosed patients with COPD, verified by spirometry in general practise and/or municipalities.

Criteria

Inclusion Criteria:

  • COPD diagnose, verified by spirometry
  • Having given informed consent

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00772733

Locations
Denmark
Research Site
Bjerringbro, Viborg, Denmark
Research Site
Moldrup, Viborg, Denmark
Research Site
Skals, Viborg, Denmark
Research Site
Aalborg, Denmark
Research Site
Arhus, Denmark
Research Site
Klarup, Denmark
Research Site
Orum, Denmark
Research Site
Skive, Denmark
Research Site
Spottrup, Denmark
Research Site
Stoholm, Denmark
Research Site
Viborg, Denmark
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Michael Skov Jensen, MD Region Hospital Viborg, DK
Study Chair: Tina Brandt Sorensen, MD Region Hospital Horsens, DK
Principal Investigator: Ove Grann Aalborg
  More Information

No publications provided

Responsible Party: Björn.E.Eriksson, MD, VP Medical, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00772733     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2007/1
Study First Received: October 14, 2008
Last Updated: February 21, 2011
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by AstraZeneca:
Quality assurance
rehabilitation
chronic care model
COPD

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
 Disease Attributes
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013